How Gilead’s remdesivir became the leader in the rush to find a treatment for COVID-19
May 01, 2020 at 15:30 PM EDT
It’s becoming more likely that the Food and Drug Administration will authorize Gilead Sciences Inc.’s remdesivir, a decade-old experimental therapy first tested on Ebola disease patients, as a COVID-19 treatment.
